Justin Balko Archives
Several from VUMC among most highly cited researchers
Nov. 17, 2022—Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis
Nov. 16, 2022—Researchers from from Vanderbilt-Ingram Cancer Center have identified the mechanism for the deadly heart inflammation myocarditis.
Breast cancer biomarkers of response
Jun. 16, 2022—Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.
Study identifies biomarker for breast cancer response to immunotherapy
Aug. 12, 2021—A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Arthritis drug may treat immunotherapy-related heart complication
Dec. 22, 2020—by Tom Wilemon A drug typically prescribed for rheumatoid arthritis may also be effective in treating a rare but potentially deadly heart complication some cancer patients experience after taking immunotherapies, according to a study published in Cancer Discovery and co-led by investigators at Vanderbilt University Medical Center. The researchers demonstrated that the drug abatacept reduced...
Health workers sought for hydroxychloroquine study
Apr. 23, 2020—Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.
Balko lands Mary Kay Foundation grant for breast cancer research
Dec. 5, 2019—Vanderbilt-Ingram Cancer Center's Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.
Encephalitis identified as rare toxicity of immunotherapy treatment
Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Cancer Center investigators awarded Komen grants
Oct. 11, 2018—Four Vanderbilt-Ingram Cancer Center (VICC) investigators have received financial support from Susan G. Komen for breast cancer research.
Study seeks to boost breast tumor immune response
Feb. 8, 2018—Immunotherapy, which harnesses the power of the immune system, is one of the most promising forms of cancer therapy and has been shown to work well against some types of cancer.
Breast cancer program lands new research grants
Mar. 23, 2017—Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.
V Foundation grants bolster cancer initiatives
Nov. 17, 2016—Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC.